November 7, 2023 News by Margarida Maia, PhD High DMT adherence lowers risk of moderate or severe relapse by 25% A high level of adherence to disease-modifying therapies (DMTs) is associated with a significant, 25% lower risk of moderate or severe relapses in previously untreated people with multiple sclerosis (MS) compared with those failing to adhere to therapy, according to a study of real-world data in Italy. High…
October 6, 2023 News by Margarida Maia, PhD How well MS patients adhere to treatment tied to certain factors People with multiple sclerosis (MS) who experience a greater number of more severe flare-ups, also known as relapses, are more likely to take their medications regularly, but less likely to keep taking them over time, a review study has found. Other factors associated with better treatment adherence and persistence…
September 20, 2023 News by Patricia Inacio, PhD First of its kind algorithm may help predict treatment adherence in MS Swoop, a consumer health data company, is launching a first of its kind algorithm that’s designed to predict treatment adherence in people with multiple sclerosis (MS) or other conditions. The aim of the new algorithm ā which is based on artificial intelligence (AI) and machine learning (ML) strategies…
June 26, 2023 News by Margarida Maia, PhD Education found to help with MS treatment adherence in Iran An educational intervention program was found to help improve treatment adherence among people with multiple sclerosis (MS) receiving injectable therapies in a clinical trial in Iran. The program was designed based on the theory of planned behavior ā a psychological premise that assumes people act rationally according to their…
May 24, 2022 News by Marta Figueiredo, PhD High Adherence to Rebif Seen With RebiSmart Use, Chats With Doctor Regular feedback from doctors about dosing data and health status is associated with high and sustained treatment adherence to RebifĀ (interferon beta-1a) amongĀ multiple sclerosis (MS)Ā patients using the RebiSmart autoinjector, a two-year observational study shows. This study’s level of treatment adherence ā 97.9% ā was comparable or superior to the…
September 25, 2020 News by Patricia Inacio, PhD MS Patients Have Higher Burden of Mental Disorders, French Study Finds People with multiple sclerosis (MS) have a higher burden of mental disorders than healthy people or people with rheumatoid arthritis, a French population-based study suggests. The study, āPrevalence of mental disorders is higher in patients with multiple sclerosis than in the general population or in patients with…
September 9, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 ā No Evidence of Disease Activity Seen in Most RRMS Patients After Switching to Ocrevus, Data Show Switching to Genentechās OcrevusĀ (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people withĀ relapsing-remitting multiple sclerosisĀ (RRMS), according to data from a Phase 3b clinical trial. That finding, as well as data about patients’ adherence and…
June 26, 2020 News by David Melamed, PhD Online Resource Center Informs MS Patients About Treatments, Adherence MyHealthTeams and EMD SeronoĀ have teamed up to launch the Treatment and Adherence Resource Center, a new informational tool within the MyMSTeam social network for people living with multiple sclerosis (MS). The new resource center is geared toward educating MS patients about the importance of starting…
March 19, 2019 News by Jonathan Grinstein Risk Tolerance for Therapies Linked to Age, Sex and Disability Sex, age, disability level, and current disease-modifying therapy use are linked to how multiple sclerosis (MS) patients weigh the potential benefits and safety risks of treatments, new research from two teams funded by the National Multiple Sclerosis SocietyĀ shows. These studies shed light on how…
December 4, 2018 News by Jose Marques Lopes, PhD RRMS Patients on Rebif Show High Treatment Adherence and Fewer Relapses in Real-World Study Patients with relapsing-remitting multiple sclerosis (RRMS) onĀ Rebif (interferon beta 1-a), using the RebiSmart autoinjector, have high treatment adherence, despite seasonal weather or temperature fluctuations, as well as fewer relapses over one year, a real-world study reports. The study, āSeasonal adherence to, and effectiveness of,…
October 20, 2016 News by Alice MelĆ£o, MSc Relapses and Dislike of Needles Among Reasons MS Patients Stop Betaferon Treatment Multiple sclerosis (MS) patients with more advanced disease, as evidenced by disability, and those more frequent relapses or aversion to needles are among the groups of peopleĀ at higher risk of discontinuing Betaferon (interferon beta-1b) treatment, researchers report. These findings may help to alert clinicians toĀ those least likely to adhere to…